Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk

European Journal of Neurology

Volumn 15, Issue 3, 2008, Pages 219-222

  Mateo, I ^a   Llorca, J ^b   Infante, J ^a   Rodriguez Rodriguez E ^a   Berciano, J ^a   Combarros, O ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

14 3 3 zeta; Alzheimer's disease; Butyrylcholinesterase; Epistasis; Gene polymorphism

Indexed keywords

14 3 3 ZETA PROTEIN; CHOLINESTERASE; PROTEIN 14 3 3; PROTEIN TYROSINE KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENE GENE INTERACTION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; PHOSPHORYLATION; PRIORITY JOURNAL; RS964917; RS983583; TAU PHOSPHORYLATION;

14-3-3 PROTEINS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 39149104664     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02059.x     Document Type: Article

References (20)

1. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. European Journal of Neuroscience 2007 25 : 59 68.
2. Umahara T, Uchihara T, Tsuchiya K, et al. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathologica 2004 108 : 279 286.
3. Hashiguchi M, Sobue K, Paudel HK. 14-3-3 ζis an effector of tau protein phosphorylation. Journal of Biological Chemistry 2000 275 : 25247 25254.
4. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Annals of Neurology 2004 55 : 815 828.
5. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. Journal of Neural Transmission 2006 113 : 1625 1644.
6. Gómez-Ramos P, Bouras C, Moran MA. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients. Brain Research 1994 640 : 17 24.
7. Jia Y, Yu X, Zhang B, et al. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. European Psychiatry 2004 19 : 377 379.
8. Wong AHC, Likhodi O, Trakalo J, et al. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophrenia Research 2005 78 : 137 146.
9. McKhaan G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDA-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 934 944.
10. Alvarez-Arcaya A, Combarros O, Llorca J, et al. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurologica Scandinavica 2000 102 : 350 353.
11. Soulié C, Nicole A, Delacourte A, Ceballos-Picot I. Examination of stress-related genes in human temporal versus occipital cortex in the course of neurodegeneration: involvement of 14-3-3 zeta in this dynamic process. Neuroscience Letters 2004 365 : 1 5.
12. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Research 2005 1060 : 144 152.
13. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. American Journal of Human Genetics 1992 50 : 1086 1103.
14. Ballard C, Morris C, Kalaria R, McKeith I, Perry R, Perry E. The K variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dementia and Geriatric Cognitive Disorders 2005 19 : 357 360.
15. Sodeyama N, Yamada M, Mizusawa H, et al. Association between butyrylcholinesterase K variant and the Alzheimer type neuropathological changes in apolipoprotein E ε4 carriers older than 75 years. Journal of Neurology, Neurosurgery and Psychiatry 1999 67 : 693 694.
16. Lehmann DJ, Williams J, McBroom J, et al. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001 108 : 541 554.
17. Hiltunen M, Mannermaa A, Helisalmi S, et al. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neuroscience Letters 1998 250 : 69 71.
18. Holmes C, Ballard C, Lehmann D, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 : 640 643.
19. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Current Medical Research and Opinion 2005 21 : 1317 1328.
20. Llorca J, Dierssen-Sotos T, Combarros O, Berciano J. Consistency in gene-Alzheimer's disease association studies. Journal of Epidemiology and Community Health 2005 59 : 83 85.